Program: Monday (24.10.2016)

07:30 – 08:30

Satellite Symposium (by Janssen Cilag GmbH) Future Directions in Lymphoma and Myeloma Therapy

  • Barbara Eichhorst
  • 07:30–07:50

    Mode of action of PD1 / PD-L1 monoclonal antibodies in HL

    • Peter Hillmen
  • 07:50–08:10

    Novel therapeutic strategies to improve outcome of patients with aggressive lymphomas

    • Georg Lenz
  • 08:10–08:30

    Targeting CD38 in Multiple Myeloma

    • Christoph Scheid

08:30 – 10:30

Scientific Session Biology and Microenvironment

  • Stephan Mathas
  • Margaret Shipp
  • 08:30–08:50

    Genetic lesions in HRS cells and their relationship to CD30+ B cells

    • Ralf Küppers
  • 08:50–09:10

    Exome-sequencing in HL

    • Enrico Tiacci
  • 09:10–09:30

    Gene expression pro ling of the HL microenvironment

    • Christian Steidl
  • 09:30–09:40

    Analysis of the mutational landscape and dynamics in Hodgkin Lymphoma using NGS

    • Juan F García
  • 09:40–09:50

    High expression of programmed cell death receptor 1 (PD-1) in the tumor microenvironment is associated with inferior event free survival in classical Hodgkin Lymphoma

    • Peter Hollander
  • 09:50–10:00

    The AP-1 transcription factor BATF3 regulates MYC expression and is required for tumor cell survival in classical Hodgkin Lymphoma and anaplastic large cell lymphoma

    • Anna Lollies

10:30 – 12:00

Scientific Session Immunotherapy (Basic Science)

  • Alison J. Moskowitz
  • Harald Stein
  • 10:30–10:50

    PD1 / PD-L1 / L2 assessment in HL

    • Margaret Shipp
  • 10:50–11:10

    Mode of action of PD1 / PD-L1 MoAbs in HL

    • Alison J. Moskowitz
  • 11:10–11:30

    Other new approaches

    • Anke van den Berg
  • 11:30–11:40

    Hodgkin Lymphoma infiltrating T cells: considering various means of tumor evasion

    • Frederik Wein
  • 11:40–11:50

    CCR5 blocking by Maraviroc inhibited recruitment, proliferation and pro- tumor e ects of mesenchymal stromal cells and monocytes in 2D and 3D models of Hodgkin Lymphoma microenvironment

    • Naike Casagrande
  • 11:50–12:00

    Disturbed antigen presentation in classical Hodgkin Lymphoma: implications for immune checkpoint inhibitor therapy?

    • Arjan Diepstra

12:15 – 13:45

Satellite Symposium (by Bristol-Myers Squibb) Evolving Therapy in the HL Treatment Landscape

  • Andreas Engert
  • 12:15–12:20

    Welcome and introductions

    • Andreas Engert
  • 12:20–12:35

    Rationale for I-O therapies in solid and hematological malignancies

    • Andreas Mackensen
  • 12:35–13:00

    Balancing the risk-benefit ratio: current treatment regimens and unmet needs in HL

    • Andreas Engert
  • 13:00–13:25

    I-O in cHL: an eye towards the future

    • Michelle Fanale
  • 13:25–13:35

    Audience Q&A session conclusions

    • Andreas Engert

14:00 – 15:30

Scientific Session PET – Where Are We?

  • Markus Dietlein
  • John Radford
  • 14:00–14:20

    PET update 2016

    • Bruce Cheson
  • 14:20–14:40

    WS report “Is PET as good as we think?”

    • Michel Meignan
  • 14:40–15:00

    Visual and quantitative PET / CT

    • Carsten Kobe
  • 15:00–15:10

    Only focal bone marrow FDG uptake in baseline FDG-PET scan has a diagnostic and prognostic impact in Hodgkin Lymphoma: results from an international collaborative study

    • Collette Zwarthoed
  • 15:10–15:20

    Strong predictive value of PET based metabolic tumor volume on survival after autologous HCT for Hodgkin Lymphoma

    • Vit Prochazka
  • 15:20–15:30

    Semi-quantitative parameters to improve the interim FDG-PET / CT positive predictive value in Hodgkin Lymphoma

    • Stefan Hohaus

16:00 – 17:30

Scientific Session Early Stages

  • Hans Theodor Eich
  • Andrew Lister
  • 16:00–16:20

    Early favorable HL: pros and cons of PET-adapted therapy

    • Martin Hutchings
  • 16:20–16:40

    Early unfavorable: new standard of care?

    • John Raemaekers
  • 16:40–17:00

    NLPHL

    • Dennis Eichenauer
  • 17:00–17:10

    Long-term follow-up of contemporary treatment in early-stage favorable Hodgkin Lymphoma (HL): updated analyses of the German Hodgkin Study Group HD7 and HD10 trial

    • Stephanie Sasse
  • 17:10–17:20

    Proton radiotherapy for mediastinal Hodgkin Lymphoma: single institution experience

  • 17:20–17:30

    Results of US intergroup trial of response-adapted chemotherapy or chemotherapy / radiation therapy based on PET for non-bulky stage I and II Hodgkin Lymphoma (HL) (CALGB / Alliance 50604)

    • David Straus

17:45 – 19:15

Satellite Symposium (by Medscape Education) Managing Hodgkin Lymphoma – A World View

  • Andreas Engert
  • Welcome and introduction

    • Andreas Engert
  • Diagnostics in practice: the ideal and the pragmatic

    • Raymond H.S. Liang
  • Prognostic indicators in front-line HL: a practical guide to individualizing therapy

    • Joseph Connors
  • Imaging and monitoring strategies: optimizing available resources

    • Astrid Pavlovsky
  • Optimizing HL management in the relapsed / refractory setting: making the most of available options

    • Andreas Engert
  • Concluding remarks

    • Andreas Engert

Archive

You a viewing the program of a past symposium. Click here to get back to the current conference.